|
 Shares of Johnson & Johnson gained 0.8% in premarket trading on Wednesday after the company said it will receive more than $1 billion from the U.S. government to manufacture 100 million doses of its investigational COVID-19 vaccine. The vaccine will be provided at a "global not-for-profit basis for emergency pandemic use," J&J said. The company's vaccine candidate recently entered the Phase 1/2a clinical trial, which is taking place in Belgium and the U.S. J&J's stock is up 0.9% year-to-date, while the S&P 500 has gained 2.3%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
|
RELATED ARTICLES | | | | |
|
Second Stimulus hopes and US-China Tensions are the two important factors that can make or break the coronavirus stock market rally. Novavax stock went wild on vaccine data news.
|
|
Novavax Phase 1 data shows coronavirus vaccine is safe and elicits an immune response CNNNovavax's coronavirus vaccine generates promising immune response in early trial, data shows CNBCNovavax shares plunge after-hours despite positive Covid-19 vaccine data CNBC TelevisionCoronavirus latest: Asia-Pacific stocks dip as recovery doubts boost gold Financial TimesNovavax's Covid-19 vaccine shows promising immune response STATView Full C
|
|
Private Label